Engage Bio
Potent, durable, and redosable non-viral genetic medicines
Acquired
Will Olsen · 1 founder
2026Acquired
AcquiredTeam
10
current
Co-founders
1
current
Stage
Acquired
Profile coverage4 of 8 · missing Funding, Signals, Customers, Stack / tools · last run 8/10/2026
About
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.